Rezolute Posts FY26 Loss, upLIFT Data Shows 7 of 8 Responders
RZLT has more than doubled off its 52-week low of $1.07 on elevated volume (2.5× avg).
Summary
Rezolute reported fiscal 2026 results with a net loss of $77.6 million and cash of $107.8 million, down from $167.9 million a year earlier. The upLIFT Phase 3 trial for tumor HI now shows 7 of 8 participants met the primary endpoint responder criterion, up from 6 at the June interim update. The sunRIZE Phase 3 study in congenital HI, which missed its primary endpoint, remains under FDA review with additional CGM-based analyses submitted. The company expects upLIFT topline results before the end of 2026. The cash position provides runway into 2027, but the FDA's decision on sunRIZE is the key binary event for the congenital HI indication.
At the time of this announcement, RZLT was trading at $3.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.4M. The 52-week trading range was $1.07 to $11.46. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.